arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Cellectar Biosciences, Inc.

CLRB
$1.15 ▼ -0.07 (-5.74%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
24 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cellectar Biosciences, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $3.0M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -212.6% ↗
FCF / Share $-8.87 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

24-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-21.79M
↑ +51.1% —
FCF / Share Free cash flow per share
$-8.87
↑ +77.3% —
Long-Term Debt Long-term obligations
$330.22K
↓ -26.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
1
Cash Quality ↑
68

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 24 years · 75 quarters